The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: A randomized, prospective, intervention study.

Bechlioulis A, Markozannes G, Chionidi I, Liberopoulos E, Naka KK, Ntzani EE, Liatis S, Rizzo M, Rizos EC

Journal of diabetes and its complications23 Feb 2023Cited by 26 (Europe PMC)

PMID36842186DOI10.1016/j.jdiacomp.2023.108436PepBankPUB-36842186

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide and empagliflozin did not differ significantly in change in pulse wave velocity at 3 months.
In plain wordsIn adults with type 2 diabetes, liraglutide and empagliflozin did not differ significantly in their effect on arterial stiffness after 3 months.
Peptide
Liraglutide
Outcome
No significant changeChange in pulse wave velocity (PWV) at 3 months
Study
n = 62
Comparator
Empagliflozin
Analysis
Primary
Outcome group
Vascular function · Cardiovascular
Studied dose
titrated to 1.8 mg · 3 monthsAs given in this study (human).
Source sentences
Summary
We failed to show any significant between-group differences of ΔPWV and ΔΑΙx at 3 and 9 months
3 context sentences(design, population, supporting numbers)
Summary · context
The primary outcome was the between-group difference of PWV change (ΔPWV) and ΔAIx at 3 months.
Summary · context
This was a randomized single blind study evaluating the effect of empagliflozin vs liraglutide in adult patients with T2D.
Summary · context
Patients were randomized to liraglutide titrated gradually to 1.8 mg or empagliflozin 25 mg in 1:1 ratio.
Report a problemFND-3684218601
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide and empagliflozin did not differ significantly in change in augmentation index at 3 months.
In plain wordsIn adults with type 2 diabetes, liraglutide and empagliflozin did not differ significantly in their effect on arterial wave reflection after 3 months.
Peptide
Liraglutide
Outcome
No significant changeChange in augmentation index (AIx) at 3 months
Study
n = 62
Comparator
Empagliflozin
Analysis
Primary
Outcome group
Vascular function · Cardiovascular
Studied dose
titrated to 1.8 mg · 3 monthsAs given in this study (human).
Source sentences
Summary
We failed to show any significant between-group differences of ΔPWV and ΔΑΙx at 3 and 9 months
3 context sentences(design, population, supporting numbers)
Summary · context
The primary outcome was the between-group difference of PWV change (ΔPWV) and ΔAIx at 3 months.
Summary · context
This was a randomized single blind study evaluating the effect of empagliflozin vs liraglutide in adult patients with T2D.
Summary · context
Patients were randomized to liraglutide titrated gradually to 1.8 mg or empagliflozin 25 mg in 1:1 ratio.
Report a problemFND-3684218602

Studies that did not test the peptide alone13

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the sequential combinations of liraglutide and empagliflozin did not differ significantly in change in pulse wave velocity at 9 months.
In plain wordsIn adults with type 2 diabetes, the two orders of adding liraglutide and empagliflozin did not differ in arterial stiffness at 9 months.
Peptide
Liraglutide
Outcome
No significant changeChange in PWV at 9 months (sequential combination)
Study
n = 62
Comparator
Empagliflozin then liraglutide
Analysis
Secondary
Outcome group
Vascular function · Cardiovascular
Source sentences
Summary
We failed to show any significant between-group differences of ΔPWV and ΔΑΙx at 3 and 9 months
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes included the between-group difference of ΔPWV and ΔAIx at 9 months, as well as the ΔPWV and ΔAIx between baseline and 9-month visit when total study population was assessed.
Summary · context
This was a randomized single blind study evaluating the effect of empagliflozin vs liraglutide in adult patients with T2D.
Summary · context
Patients were randomized to liraglutide titrated gradually to 1.8 mg or empagliflozin 25 mg in 1:1 ratio.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3684218603
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the sequential combinations of liraglutide and empagliflozin did not differ significantly in change in augmentation index at 9 months.
In plain wordsIn adults with type 2 diabetes, the two orders of adding liraglutide and empagliflozin did not differ in arterial wave reflection at 9 months.
Peptide
Liraglutide
Outcome
No significant changeChange in AIx at 9 months (sequential combination)
Study
n = 62
Comparator
Empagliflozin then liraglutide
Analysis
Secondary
Outcome group
Vascular function · Cardiovascular
Source sentences
Summary
We failed to show any significant between-group differences of ΔPWV and ΔΑΙx at 3 and 9 months
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes included the between-group difference of ΔPWV and ΔAIx at 9 months, as well as the ΔPWV and ΔAIx between baseline and 9-month visit when total study population was assessed.
Summary · context
This was a randomized single blind study evaluating the effect of empagliflozin vs liraglutide in adult patients with T2D.
Summary · context
Patients were randomized to liraglutide titrated gradually to 1.8 mg or empagliflozin 25 mg in 1:1 ratio.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3684218604
05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, no significant change in pulse wave velocity was shown from baseline to 9 months across the whole study population.
In plain wordsIn adults with type 2 diabetes, arterial stiffness did not change significantly over 9 months across the whole group given either drug order.
Peptide
Liraglutide
Outcome
No significant changeChange in PWV from baseline to 9 months, total population
Study
n = 62
Analysis
Secondary
Outcome group
Vascular function · Cardiovascular
Source sentences
Summary
as well as between-group difference of ΔPWV and ΔAIx for the total study population between baseline and 9-month visit.
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes included the between-group difference of ΔPWV and ΔAIx at 9 months, as well as the ΔPWV and ΔAIx between baseline and 9-month visit when total study population was assessed.
Summary · context
This was a randomized single blind study evaluating the effect of empagliflozin vs liraglutide in adult patients with T2D.
Summary · context
Patients were randomized to liraglutide titrated gradually to 1.8 mg or empagliflozin 25 mg in 1:1 ratio.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3684218605
06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, no significant change in augmentation index was shown from baseline to 9 months across the whole study population.
In plain wordsIn adults with type 2 diabetes, arterial wave reflection did not change significantly over 9 months across the whole group given either drug order.
Peptide
Liraglutide
Outcome
No significant changeChange in AIx from baseline to 9 months, total population
Study
n = 62
Analysis
Secondary
Outcome group
Vascular function · Cardiovascular
Source sentences
Summary
as well as between-group difference of ΔPWV and ΔAIx for the total study population between baseline and 9-month visit.
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes included the between-group difference of ΔPWV and ΔAIx at 9 months, as well as the ΔPWV and ΔAIx between baseline and 9-month visit when total study population was assessed.
Summary · context
This was a randomized single blind study evaluating the effect of empagliflozin vs liraglutide in adult patients with T2D.
Summary · context
Patients were randomized to liraglutide titrated gradually to 1.8 mg or empagliflozin 25 mg in 1:1 ratio.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3684218606
07HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, systemic vascular resistance improved, with better results with liraglutide than with empagliflozin.
In plain wordsIn adults with type 2 diabetes, systemic vascular resistance improved, with better results for liraglutide than empagliflozin.
Peptide
Liraglutide
Outcome
Direction not reportedSystemic vascular resistance
Study
n = 62
Comparator
Empagliflozin
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
In contrast, systemic vascular resistance and lipoprotein(a) levels improved, showing better results with liraglutide than empagliflozin.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized single blind study evaluating the effect of empagliflozin vs liraglutide in adult patients with T2D.
Summary · context
Patients were randomized to liraglutide titrated gradually to 1.8 mg or empagliflozin 25 mg in 1:1 ratio.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3684218607
08HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, lipoprotein(a) levels improved, with better results with liraglutide than with empagliflozin.
In plain wordsIn adults with type 2 diabetes, lipoprotein(a) levels improved, with better results for liraglutide than empagliflozin.
Peptide
Liraglutide
Outcome
Direction not reportedLipoprotein(a)
Study
n = 62
Comparator
Empagliflozin
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
In contrast, systemic vascular resistance and lipoprotein(a) levels improved, showing better results with liraglutide than empagliflozin.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized single blind study evaluating the effect of empagliflozin vs liraglutide in adult patients with T2D.
Summary · context
Patients were randomized to liraglutide titrated gradually to 1.8 mg or empagliflozin 25 mg in 1:1 ratio.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3684218608
09HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes given liraglutide and empagliflozin, favorable effects on body weight were observed.
In plain wordsIn adults with type 2 diabetes given liraglutide and empagliflozin, body weight changed favorably.
Peptide
Liraglutide
Outcome
Direction not reportedBody weight
Study
n = 62
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Favorable effects were also observed on body weight, body mass index, body and visceral fat, blood pressure, HbA1c, and uric acid levels.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized single blind study evaluating the effect of empagliflozin vs liraglutide in adult patients with T2D.
Summary · context
Patients were randomized to liraglutide titrated gradually to 1.8 mg or empagliflozin 25 mg in 1:1 ratio.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3684218609
10HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes given liraglutide and empagliflozin, favorable effects on body mass index were observed.
In plain wordsIn adults with type 2 diabetes given liraglutide and empagliflozin, body mass index changed favorably.
Peptide
Liraglutide
Outcome
Direction not reportedBody mass index
Study
n = 62
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Favorable effects were also observed on body weight, body mass index, body and visceral fat, blood pressure, HbA1c, and uric acid levels.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized single blind study evaluating the effect of empagliflozin vs liraglutide in adult patients with T2D.
Summary · context
Patients were randomized to liraglutide titrated gradually to 1.8 mg or empagliflozin 25 mg in 1:1 ratio.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3684218610
11HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes given liraglutide and empagliflozin, favorable effects on body fat were observed.
In plain wordsIn adults with type 2 diabetes given liraglutide and empagliflozin, body fat changed favorably.
Peptide
Liraglutide
Outcome
Direction not reportedBody fat
Study
n = 62
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Favorable effects were also observed on body weight, body mass index, body and visceral fat, blood pressure, HbA1c, and uric acid levels.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized single blind study evaluating the effect of empagliflozin vs liraglutide in adult patients with T2D.
Summary · context
Patients were randomized to liraglutide titrated gradually to 1.8 mg or empagliflozin 25 mg in 1:1 ratio.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3684218611
12HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes given liraglutide and empagliflozin, favorable effects on visceral fat were observed.
In plain wordsIn adults with type 2 diabetes given liraglutide and empagliflozin, visceral fat changed favorably.
Peptide
Liraglutide
Outcome
Direction not reportedVisceral fat
Study
n = 62
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Favorable effects were also observed on body weight, body mass index, body and visceral fat, blood pressure, HbA1c, and uric acid levels.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized single blind study evaluating the effect of empagliflozin vs liraglutide in adult patients with T2D.
Summary · context
Patients were randomized to liraglutide titrated gradually to 1.8 mg or empagliflozin 25 mg in 1:1 ratio.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3684218612
13HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes given liraglutide and empagliflozin, favorable effects on blood pressure were observed.
In plain wordsIn adults with type 2 diabetes given liraglutide and empagliflozin, blood pressure changed favorably.
Peptide
Liraglutide
Outcome
Direction not reportedBlood pressure
Study
n = 62
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
Favorable effects were also observed on body weight, body mass index, body and visceral fat, blood pressure, HbA1c, and uric acid levels.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized single blind study evaluating the effect of empagliflozin vs liraglutide in adult patients with T2D.
Summary · context
Patients were randomized to liraglutide titrated gradually to 1.8 mg or empagliflozin 25 mg in 1:1 ratio.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3684218613
14HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes given liraglutide and empagliflozin, favorable effects on HbA1c were observed.
In plain wordsIn adults with type 2 diabetes given liraglutide and empagliflozin, HbA1c changed favorably.
Peptide
Liraglutide
Outcome
Direction not reportedHbA1c
Study
n = 62
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Favorable effects were also observed on body weight, body mass index, body and visceral fat, blood pressure, HbA1c, and uric acid levels.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized single blind study evaluating the effect of empagliflozin vs liraglutide in adult patients with T2D.
Summary · context
Patients were randomized to liraglutide titrated gradually to 1.8 mg or empagliflozin 25 mg in 1:1 ratio.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3684218614
15HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes given liraglutide and empagliflozin, favorable effects on uric acid levels were observed.
In plain wordsIn adults with type 2 diabetes given liraglutide and empagliflozin, uric acid levels changed favorably.
Peptide
Liraglutide
Outcome
Direction not reportedUric acid
Study
n = 62
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Source sentences
Summary
Favorable effects were also observed on body weight, body mass index, body and visceral fat, blood pressure, HbA1c, and uric acid levels.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized single blind study evaluating the effect of empagliflozin vs liraglutide in adult patients with T2D.
Summary · context
Patients were randomized to liraglutide titrated gradually to 1.8 mg or empagliflozin 25 mg in 1:1 ratio.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3684218615

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.